| Title |
Behavioural toxicity of antidepressants with particular reference to moclobemide
|
|---|---|
| Published in |
Psychopharmacology, February 1992
|
| DOI | 10.1007/bf02246236 |
| Pubmed ID | |
| Authors |
I. Hindmarch, J. Kerr |
| Abstract |
The clinical decision to use a particular antidepressant should be made with reference to the behavioural toxicity profiles of substances in current use. Antidepressants can be cardiotoxic, proconvulsant, able to cause weight gain and sleep disturbance, and also impair psychological functions necessary for everyday living. Behavioural toxicity (reduction in psychomotor activity or cognitive ability) tends to augment levels of psychomotor and cognitive retardation; meta-analysis of controlled studies of antidepressants shows that some tricyclics can disrupt these functions. In comparison with these, moclobemide is relatively free from significant behavioural toxicity within the dose-ranges used. No relevant differences were found between placebo and 200 mg moclobemide on a battery of psychomotor and cognitive tests: with 400 mg, there was a significant impairment of peripheral reaction time, but no other measure of the test battery was impaired. In comparison, amitriptyline 50 mg, produced a noticeable and significant impairment of psychomotor and cognitive skills on most test measures. On the whole moclobemide has been found to be free from any behavioural toxicity likely to interfere with the well-being of patients or their performance of the tasks of everyday living. |
Mendeley readers
The data shown below were compiled from readership statistics for 9 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 9 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Doctoral Student | 1 | 11% |
| Professor | 1 | 11% |
| Student > Ph. D. Student | 1 | 11% |
| Researcher | 1 | 11% |
| Student > Postgraduate | 1 | 11% |
| Other | 0 | 0% |
| Unknown | 4 | 44% |
| Readers by discipline | Count | As % |
|---|---|---|
| Philosophy | 1 | 11% |
| Psychology | 1 | 11% |
| Medicine and Dentistry | 1 | 11% |
| Unknown | 6 | 67% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 May 2017.
All research outputs
#8,515,843
of 25,380,192 outputs
Outputs from Psychopharmacology
#2,238
of 5,371 outputs
Outputs of similar age
#12,516
of 61,719 outputs
Outputs of similar age from Psychopharmacology
#5
of 26 outputs
Altmetric has tracked 25,380,192 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 5,371 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.0. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 61,719 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 19th percentile – i.e., 19% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.